Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016999 | 0.80 | SYK (0.65) | SYK | |
| SCHEMBL1983851 | 0.79 | SYK (0.85) | SYK | |
| SCHEMBL16205294 | 0.77 | SYK (0.56) | SYK | |
| SCHEMBL5077242 | 0.77 | SYK (0.71) | SYK | |
| SCHEMBL16200899 | 0.77 | SYK (0.58) | SYK | |
| SCHEMBL5080766 | 0.76 | SYK (0.69) | SYK | |
| SCHEMBL2045722 | 0.75 | SYK (0.60) | SYK | |
| SCHEMBL28020002 | 0.75 | SYK (0.56) | SYK | |
| SCHEMBL19347487 | 0.75 | SYK (1.00) | SYK | |
| SCHEMBL2043550 | 0.74 | SYK (0.48) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513098-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | SYK 1/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.